ELCC 2026: Six-Year Outcomes of the EMPOWER-LUNG-1 Trial in Advanced NSCLC

Dr. Saadettin Kılıçkap presents long-term, six-year follow-up results from the EMPOWER-LUNG-1 phase III trial evaluating first-line cemiplimab versus chemotherapy in advanced non-small cell lung cancer with high PD-L1 expression. The analysis confirms sustained overall survival benefit, improved response outcomes across histologies and PD-L1 subgroups, and durable efficacy after two years of treatment, with an acceptable long-term safety profile.